Recent studies have identified IGSF8 as an innate immune checkpoint and tumor immunotherapeutic target.226 The newly developed IGSF8.06 antibody can block the inhibitory effect of IGSF8 expressed on tumors on NK cell function, thus stimulating NK cells to kill malignant cells with antigen presentation defects and stress signals.226. Here, IGSF8 is linked to neoplasm.